| Melissa F Efron-everett, MD | |
|
13943 N 91st Ave, Suite C-101, Peoria, AZ 85381-3629 | |
| (623) 972-3992 | |
| (623) 977-1132 |
| Full Name | Melissa F Efron-everett |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 13 Years |
| Location | 13943 N 91st Ave, Peoria, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588956361 | NPI | - | NPPES |
| 34459 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 50382 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southwest Skin Specialists Llc | 9739079864 | 47 |
News Archive
Alvine Pharmaceuticals, Inc. today announced the presentation of data from a Phase 2A trial of its lead compound, ALV003, at the 2012 Digestive Diseases Week (DDW) meeting held in San Diego, California. The study results met the primary endpoint of demonstrating that oral ALV003, administered in the context of a gluten free diet (GFD), can diminish gluten-induced intestinal mucosal injury in well-controlled celiac disease patients. The company plans to initiate a Phase 2B trial later this year.
Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of chemotherapy for some cancer patients.
BioSante Pharmaceuticals, Inc. today announced it has been added to the broad-market Russell 3000 Index as part of Russell Investments' recent reconstitution of its comprehensive set of U.S. and global equity indexes which occurred after market close on June 25, 2010.
Doctors in the U.S. have come up with a program which they hope will encourage the relatives and friends of lung cancer victims to quit smoking.
› Verified 5 days ago
| Entity Name | Southwest Skin Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174521926 PECOS PAC ID: 9739079864 Enrollment ID: O20040319001063 |
News Archive
Alvine Pharmaceuticals, Inc. today announced the presentation of data from a Phase 2A trial of its lead compound, ALV003, at the 2012 Digestive Diseases Week (DDW) meeting held in San Diego, California. The study results met the primary endpoint of demonstrating that oral ALV003, administered in the context of a gluten free diet (GFD), can diminish gluten-induced intestinal mucosal injury in well-controlled celiac disease patients. The company plans to initiate a Phase 2B trial later this year.
Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of chemotherapy for some cancer patients.
BioSante Pharmaceuticals, Inc. today announced it has been added to the broad-market Russell 3000 Index as part of Russell Investments' recent reconstitution of its comprehensive set of U.S. and global equity indexes which occurred after market close on June 25, 2010.
Doctors in the U.S. have come up with a program which they hope will encourage the relatives and friends of lung cancer victims to quit smoking.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melissa F Efron-everett, MD 13128 N 94th Dr, Suite 200, Peoria, AZ 85381-4254 Ph: (623) 760-9449 | Melissa F Efron-everett, MD 13943 N 91st Ave, Suite C-101, Peoria, AZ 85381-3629 Ph: (623) 972-3992 |
News Archive
Alvine Pharmaceuticals, Inc. today announced the presentation of data from a Phase 2A trial of its lead compound, ALV003, at the 2012 Digestive Diseases Week (DDW) meeting held in San Diego, California. The study results met the primary endpoint of demonstrating that oral ALV003, administered in the context of a gluten free diet (GFD), can diminish gluten-induced intestinal mucosal injury in well-controlled celiac disease patients. The company plans to initiate a Phase 2B trial later this year.
Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of chemotherapy for some cancer patients.
BioSante Pharmaceuticals, Inc. today announced it has been added to the broad-market Russell 3000 Index as part of Russell Investments' recent reconstitution of its comprehensive set of U.S. and global equity indexes which occurred after market close on June 25, 2010.
Doctors in the U.S. have come up with a program which they hope will encourage the relatives and friends of lung cancer victims to quit smoking.
› Verified 5 days ago
Lori-ann R Wilcox, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 13943 N 91st Ave, C-101, Peoria, AZ 85381 Phone: 623-760-9449 Fax: 623-974-9351 | |
Deborah Zell, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 13943 N 91st Ave, #c-1, Peoria, AZ 85381 Phone: 623-972-3992 Fax: 623-583-4074 | |
Mary F Fredenberg, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 14155 N 83rd Ave, Suite #110, Peoria, AZ 85381 Phone: 623-215-0911 Fax: 623-215-0912 | |
Dr. Julie Jacobs, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 14155 N 83rd Ave Ste 110, Peoria, AZ 85381 Phone: 623-888-8145 | |
Dr. Troy C Ellis, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 13943 N 91st Ave, #c-101, Peoria, AZ 85381 Phone: 623-760-9449 Fax: 623-974-9351 | |
Douglas Heiner, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 14155 N 83rd Ave Ste 110, Peoria, AZ 85381 Phone: 623-215-0911 | |
Dr. Rosemary Theresa Depaoli, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 7767 W Deer Valley Rd Ste 140, Peoria, AZ 85382 Phone: 623-487-3003 Fax: 623-889-7137 |